Hollow-Bore Needlestick when the Source Patient Refuses Testing
A 26-year-old registered nurse sustains a needlestick while placing an intravenous line in an agitated patient in the emergency department. The device is a hollow-bore needle that had just been used to draw blood; it penetrates the pad of her left index finger deeply, and the needle is visibly blood-filled. She was not wearing gloves. She completed a hepatitis B vaccine series and has a documented anti-HBs of 45 mIU/mL from three years ago. She has never been tested for HIV or hepatitis C, is not pregnant, and takes carbamazepine for epilepsy. The source patient is a 34-year-old man with a history of injection drug use who is alert and has capacity. He refuses HIV, hepatitis B and hepatitis C testing, saying he does not want 'that on my record'. The exposure occurred 60 minutes ago, and the nurse is tearful and asking whether she will become infected.
1. Assess the transmission risk and prescribe post-exposure management, including drug choice and dose.
Read the worked answer
Risk assessment: a deep, hollow-bore, blood-filled needle without gloves is a high-risk percutaneous exposure. Average HIV transmission from a percutaneous exposure to HIV-infected blood is about 0.3%, higher with a larger inoculum (visible blood in the device, deep injury, a source with high viral load). Hepatitis C transmission is roughly 1.8%; hepatitis B would be the highest of all, but she is immune - a documented anti-HBs of 45 mIU/mL is well above the 10 mIU/mL protective threshold, so no hepatitis B immunoglobulin or vaccine booster is required.
Start HIV PEP now - do not wait for the source patient's results. Regimen: tenofovir disoproxil fumarate 300 mg plus emtricitabine 200 mg once daily, with dolutegravir 50 mg once daily, for 28 days. Because she takes carbamazepine, a potent enzyme inducer, dolutegravir must be dosed 50 mg twice daily for the duration of PEP.
Baseline tests: HIV antigen/antibody, hepatitis C antibody, hepatitis B surface antigen and anti-HBs (to document immunity), full blood count, creatinine and liver enzymes, pregnancy test, and a hepatitis C RNA at 4–6 weeks if local protocol supports early detection.
Counsel: side effects (nausea, headache, insomnia), adherence support, no need to avoid work, and the plan to stop PEP if the source is later confirmed HIV-negative.
2. The source patient has capacity and refuses all testing. How do you handle this - ethically and legally - without breaching either party's confidentiality?
Read the worked answer
This is a genuine conflict between the nurse's need for information and the patient's autonomy and confidentiality, and it should be managed in a structured, documented way rather than by covert action.
First, counsel the source patient. Explain what is being asked, why, and what will happen to the result - that only the minimum necessary information will be shared with occupational health, that the nurse will not be told his identity or his results beyond what affects her care, and that testing is voluntary. Address his stated concern about 'it being on my record' - explain confidentiality protections and any anonymous coding available. Many refusals soften at this point.
Second, know the law. Many jurisdictions specifically permit source-patient testing after a significant occupational exposure without consent, using a statutory process (often involving an authorised medical officer, a court order, or a public health authority), with results disclosed only to the exposed worker to the extent needed to guide prophylaxis. Check your state or national statute and institutional policy; do not assume consent is required, and do not assume it can be overridden.
Third, escalate appropriately: occupational health, infection control, the ethics committee and hospital legal counsel. Document the counselling, the refusal, and the legal advice.
Never: test leftover blood covertly, disclose the nurse's status to the patient, or disclose the patient's results to anyone outside the exposure-management pathway. Continue PEP in the meantime.
3. Assuming the source remains untested, outline the follow-up schedule and the advice you give about the next six months.
Read the worked answer
HIV. Fourth-generation HIV antigen/antibody testing at baseline, 6 weeks, 12 weeks and 6 months after exposure. The 6-month test can be omitted if a fourth-generation assay is used and the source is confirmed negative; with an untested source, complete the 6-month test. A negative 4th-generation test at 6 weeks is highly reassuring but not definitive.
Hepatitis C. Anti-HCV at baseline and 6 months, plus HCV RNA at 4–6 weeks if available, because antibody seroconversion can lag. No post-exposure prophylaxis exists; if RNA becomes positive, refer promptly for direct-acting antiviral therapy, which now cures over 95% of acute infections.
Hepatitis B. No further follow-up is required given documented immunity, but confirm the anti-HBs result is in the record.
Medication monitoring. Full blood count and renal function at baseline and at 2–4 weeks on tenofovir; review adherence and side effects at 2 weeks and 4 weeks; confirm the dolutegravir dose is twice daily while she remains on carbamazepine.
Counselling. The overall risk is low and she is not infectious to others during this period, but she should use condoms or avoid unprotected sex and refrain from blood or tissue donation until the 6-month tests are negative; she may continue working with standard precautions. Advise her to report any febrile illness, rash, jaundice or fatigue. Offer psychological support - the anxiety after a needlestick is substantial and often undertreated.